RxDoctor Payments Data

Daniel Oconnor, MD

Cardiovascular Disease · New York, NYNPI 1437311800

Payments from drug & device makers

$3,354in general payments, 2019–2025

Across 122 payments — averaging $27.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$482
  • Novartis$347
  • Medtronic$333
  • Heartflow, Inc.$306
  • AstraZeneca$290
  • Abbott$255
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,354100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,354 in reported general payments places this provider in the 60th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$331,482
Medicare patients
783
Services billed
2,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban386$470,626
EntrestoSacubitril/Valsartan159$198,961
XareltoRivaroxaban107$114,597
Repatha SureclickEvolocumab58$73,648
JardianceEmpagliflozin52$56,515
FarxigaDapagliflozin Propanediol29$29,465
OzempicSemaglutide19$21,539
MultaqDronedarone Hcl14$16,465
MounjaroTirzepatide11$13,693
Metoprolol Succinate584$11,204
Atorvastatin Calcium584$7,585
Rosuvastatin Calcium482$6,470
Amlodipine Besylate493$4,260
Diltiazem 12hr ErDiltiazem Hcl19$4,195
Losartan Potassium286$3,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$470,626386 claims
NovartisEntresto$347$198,961159 claims
Johnson & JohnsonXarelto$230$114,597107 claims
Boehringer IngelheimJardiance$482$56,51552 claims
AstraZenecaFarxiga$290$29,46529 claims
Novo NordiskOzempic$102$21,53919 claims
Sanofi-aventis U.S. LLCMultaq$25$16,46514 claims
Lilly USA, LLCMounjaro$43$13,69311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →